Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis

SKINmed

Volumn 8, Issue 2, 2010, Pages 72-79

  Abramovits, William ^a,b,c   Oquendo, Marcial ^c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Dermatology Treatment and Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; HYDROCORTISONE;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; BODY SURFACE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; MALE; MULTICENTER STUDY; OINTMENT; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; BODY SURFACE AREA; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; FEMALE; HUMANS; HYDROCORTISONE; INFANT; MALE; OINTMENTS;

EID: 77954569945     PISSN: 15409740     EISSN: 17517125     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Williams HC, Grindlay DJ. What’s new in atopic eczema? An analysis of systematic reviews published in 2007 and 2008. Part 1. Definitions, causes and consequences of eczema. Clin Exp Dermatol. 2010;35:12-15. Epub Oct 23, 2009.
2. Abramovits W. Atopic dermatitis. J Am Acad Dermatol. 2005;53(1 suppl 1):S86-93.
3. Williams H, Stewart A, von Mutius E, et al. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121:947-954.
4. Locoid Lipocream Package Insert. Ferndale Laboratories, Inc. Ferndale, MI 48220.
5. Fowler JF Jr, Fransway AF, Jackson JM, et al. Hydrocortisone butyrate 0.1% cream in the treatment of chronic dermatitis. Cutis. 2005;75:125-131.
6. Aksoy MO, Li X, Borenstein M, et al. Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells. J Allergy Clin Immunol. 1999;103:1081-1091.
7. Drake LA, Dinehart SM, Farmer ER. Guidelines of care for the use of topical glucocorticosteroids. J Am Acad Dermatol. 1996;35:615-619.
8. Cook D. FDA experience: topical corticosteroids and HPA axis suppression. Pediatric subcommittee of the AIDAC. Oct. 29-30, 2003.
9. Hengge U, Ruzicka T, Schwartz R, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1-15.
10. Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11-18.
11. Brenninkmeijer EE, Schram ME, Leeflang MM, et al. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol. 2008;158:754-765. Epub Jan 30, 2008.
12. Ricci G, Dondi A, Patrizi A. Useful tools for the management of atopic dermatitis. Am J Clin Dermatol. 2009;10:287-300.
13. Dohil MA, Alvarez-Connelly E, Eichenfield LF. Fluocinolone acetonide 0.01% in peanut oil: safety and efficacy data in the treatment of childhood atopic dermatitis in infants as young as 3 months of age. Pediatr Dermatol. 2009;26:262-268.
14. Eichenflied LF, Basu S, Calvarese B, et al. Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis. Pediatr Dermatol. 2007;24:289-295.
15. Hebert AA, Cook-Bolden FE, Basu S, et al. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J Drugs Dermatol. 2007;6:157-181.
16. Hebert AA, Friedlander SF, Allen DB. Topical fluticasone propionate lotion does not cause HPA axis suppression. J Pediatr. 2006;149:378-382.
17. Friedlander SF, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol. 2002;46:387-393.
18. Moshang T. Prednicarbate emollient cream 0.1% in pediatric patients with atopic dermatitis. Cutis. 2001;68:63-69.
19. Lucky AW, Grote GD, Williams JL, et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis. 1997;59:151-153.
20. Ellison JA, Patel L, Ray DW, et al. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics. 2000;105(4 pt 1):794-799.
21. Coureau B, Bussieres JF, Tremblay S. Cushing’s syndrome induced by misuse of moderate-to high-potency topical corticosteroids. Ann Pharmacother. 2008;42:1903-1907. Epub Nov 18, 2008.
22. Güven A, Gülümser O, Ozgen T. Cushing’s syndrome and adrenocortical insufficiency caused by topical steroids: misuse or abuse? J Pediatr Endocrinol Metab. 2007;20:1173-1182.
23. Ozon A, Cetinkaya S, Alikasifoglu A, et al. Inappropriate use of potent topical glucocorticoids in infants. J Pediatr Endocrinol Metab. 2007;20:219-225.
24. Fleischer AB Jr, Feldman SR. Prescription of high-potency corticosteroid agents and clotrimazole-betamethasone dipropionate by pediatricians. Clin Ther. 1999;21:1725-1731.